Movement Disorders Clinical Trial
Official title:
A Feasibility Study of MRgFUS in the Treatment of Therapy-Resistant Tremor-Related Patients With Low SDR Value
A study to evaluate the effectiveness and safety of ExAblate transcranial MRgFUS Thalamotomy treatment of medication refractory tremor-related diseases subjects with low skull density ratio (SDR) value. Essential tremor (ET) and Parkinson disease (PD) are the most prevalent tremor disorders. ET, considered as a pure tremor disease, is characterized by upper limb intention or postural tremor, while PD is characterized by a variety of motor and non-motor symptoms, among them rest tremor. A number of studies have demonstrated that Magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy is a minimally invasive and effective procedure suitable for medication-refractory tremor in patients with ET and patients with PD. However, the skull is the main barrier to MRgFUS thalamotomy therapy and patients are screened by calculating SDR value before treatment. The US FDA recommended SDR value >0.45±0.05 as the inclusion criterion for screening patients with tremor treated by MRgFUS system. However, about 20%-50% of patients with SDR value are lower than this standard, which makes this part of patients excluded and unable to accept this treatment with many advantages such as non-invasive, no need for general anesthesia, and no need for hardware implantation. Therefore, this study intended to evaluate the safety and effectiveness of MRgFUS thalamotomy in the treatment of tremor-related patients with low SDR value, so as to provide clinical basis for more patients with tremor to benefit from this treatment.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | December 1, 2025 |
Est. primary completion date | December 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years to 99 Years |
Eligibility | Inclusion Criteria: 1. Men and women age 22 years or older; 2. Subjects are able and willing to agree to participate in the study and can accept all research visits; 3. A diagnosis of ET and PD as confirmed from clinical history and examination by a neurologist or neurosurgeon specialized in movement disorder and intolerance to side effects of medication or poor response to medication, severe and disabling tremor; 4. Able to adapt to MRI system; 5. To tolerate operation with or without some form of sedative (e.g., awake sedation); 6. Able to communicate with the doctor during the operation; 7. Able to use the "Stop ultrasonic processing" button; 8. Skull density ratio (SDR) = 0.28. Exclusion Criteria: 1. Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, known intolerance or allergies to the MRI contrast agent (e.g.Gadolinium or Magnevist) including advanced kidney disease, etc; 2. Pregnant woman; 3. Subjects with severely impaired renal function; 4. Subjects with unstable cardiac status or severe hypertension (diastolic BP > 100 on medication); 5. Subjects show behaviors consistent with alcohol or drug abuse; 6. History of abnormal bleeding and/or coagulopathy/ or intracranial hemorrhage; 7. Patients who received anticoagulant therapy or medications known to increase the risk of bleeding within the month prior to receiving focused ultrasound treatment; 8. Cerebrovascular disease (multiple CVA or CVA within 3 months); 9. Subjects with brain tumors. 10. Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (can be up to 2 hrs of total time). |
Country | Name | City | State |
---|---|---|---|
China | Chinese PLA General Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Chinese PLA General Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 1.1 Safety To evaluate the incidence and severity of adverse events (AE/AEs) associated with ExAblate Transcranial MRgFUS treatment of subjects during 2-year follow-up. | All AE reported by the investigator are classified as: definitely relevant, very likely relevant, probably relevant, probably not relevant or definitely not relevant to the product under study, where definitely relevant, very likely relevant, possibly relevant are classified as relevant, probably not relevant and definitely not relevant are classified as irrelevant. | 2 years | |
Secondary | 2.1. Safety To evaluate the incidence and severity of adverse events (AE/AEs) after ExAblate Transcranial MRgFUS treatment of subjects at 24 hours, 1 month, 3 months, 6 months, 12 months, and 2 years follow-up. | To evaluate the incidence of unexpected adverse device events (UADE) within 2 years after the treatment of the study product. | 2 years | |
Secondary | 2.2. Effectiveness | The effectiveness will be evaluated by the hand tremor subscore (on a scale ranging from 0 to 32 when the dominant hand is treated and 0 to 28 points when the nondominant hand is treated, with higher scores indicating more severe tremor), which was derived from the Clinical Rating Scale for Tremor (CRST) . Both the treatment side and the non-treatment side of the subject will be evaluated.
Clinical evaluation will be conducted at the following time points: at screening, at baseline, and 1, 3, 6, 12 months, and 2 years after treatment. |
2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05623644 -
Multimodal MR Imaging Study on ET and PD Patients Subjected With MRgFUS Thalamotomy
|
||
Active, not recruiting |
NCT03548779 -
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
|
N/A | |
Completed |
NCT03295786 -
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT03722212 -
Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test
|
N/A | |
Recruiting |
NCT05973929 -
Movement Disorders in Multiple Sclerosis Patients
|
||
Terminated |
NCT02823158 -
Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM
|
N/A | |
Enrolling by invitation |
NCT01210781 -
Target Planning for Placement of DBS-electrodes and Follow-up of the Clinical Efficacy of Stimulation
|
||
Enrolling by invitation |
NCT00355927 -
Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.
|
N/A | |
Completed |
NCT00037167 -
Effects of Exercise Poles on Older Adults During Exercise Walking
|
Phase 1/Phase 2 | |
Recruiting |
NCT04784494 -
MST for Parkinson's Disease
|
N/A | |
Terminated |
NCT03270189 -
Effect of the Visual Information Change in Functional Dystonia
|
N/A | |
Recruiting |
NCT04061135 -
Neurophysiological, Behavioral, and Cognitive Networks in Movement Disorders
|
N/A | |
Recruiting |
NCT04176692 -
The Effects of Muscle Characteristics on the Control of Shoulder Complex During Functional Movements
|
||
Suspended |
NCT04912115 -
Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia
|
Phase 2 | |
Completed |
NCT00500994 -
Neurobiology of Functional Movement Disorder and Non-Epileptic Seizures
|
Early Phase 1 | |
Completed |
NCT04536987 -
Robot Therapy for Rehabilitation of Hand Movement After Stroke
|
Phase 2 | |
Recruiting |
NCT00001208 -
Botulinum Toxin for the Treatment of Involuntary Movement Disorders
|
||
Completed |
NCT02392078 -
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
|
||
Completed |
NCT00552474 -
Deep Brain Stimulation to Treat Symptoms of Parkinson's Disease
|
N/A | |
Not yet recruiting |
NCT05032911 -
Sensorimotor Control in People With and Without Neck Pain
|